Literature DB >> 19875936

Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Aseem Pandey1, Neetu Singh, Suryaprakash Sambhara, Suresh K Mittal.   

Abstract

The emergence of a highly pathogenic H5N1 influenza virus in Hong Kong in 1997 and the subsequent appearance of other H5N1 strains and their spread to several countries in southeast Asia, Africa, the Middle East and Europe has evoked fear of a global influenza pandemic. Vaccines offer the best hope to combat the threat of an influenza pandemic. However, the global demand for a pandemic vaccine cannot be fulfilled by the current egg-based vaccine manufacturing strategies, thus creating a need to explore alternative technologies for vaccine production and delivery. Several egg-independent vaccine approaches such as cell culture-derived whole virus or subvirion vaccines, recombinant protein-based vaccines, virus-like particle (VLP) vaccines, DNA vaccines and viral vector-based vaccines are currently being investigated and appear promising both in preclinical and clinical studies. The present review will highlight the various egg-independent alternative vaccine approaches for pandemic influenza.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19875936      PMCID: PMC2888842          DOI: 10.4161/hv.6.2.9899

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  124 in total

1.  A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

Authors:  Mary A Hoelscher; Neetu Singh; Sanjay Garg; Lakshmi Jayashankar; Vic Veguilla; Aseem Pandey; Yumi Matsuoka; Jacqueline M Katz; Ruben Donis; Suresh K Mittal; Suryaprakash Sambhara
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

2.  Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

Authors:  J J Treanor; R F Betts; G E Smith; E L Anderson; C S Hackett; B E Wilkinson; R B Belshe; D C Powers
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

3.  Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

Authors:  A D Altstein; A K Gitelman; Y A Smirnov; L M Piskareva; L G Zakharova; G V Pashvykina; M M Shmarov; O P Zhirnov; N P Varich; P O Ilyinskii; A M Shneider
Journal:  Arch Virol       Date:  2005-11-15       Impact factor: 2.574

4.  The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses.

Authors:  J S Robertson; C Nicolson; D Major; E W Robertson; J M Wood
Journal:  J Gen Virol       Date:  1993-10       Impact factor: 3.891

5.  Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.

Authors:  Leo L M Poon; Y H Connie Leung; John M Nicholls; Pin-Yu Perera; Jack H Lichy; Masafumi Yamamoto; Thomas A Waldmann; J S Malik Peiris; Liyanage P Perera
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

6.  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Authors:  Mary A Hoelscher; Sanjay Garg; Dinesh S Bangari; Jessica A Belser; Xiuhua Lu; Iain Stephenson; Rick A Bright; Jacqueline M Katz; Suresh K Mittal; Suryaprakash Sambhara
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

7.  Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

Authors:  Jennifer A Schwartz; Linda Buonocore; Anjeanette Roberts; Amorsolo Suguitan; Darwyn Kobasa; Gary Kobinger; Heinz Feldmann; Kanta Subbarao; John K Rose
Journal:  Virology       Date:  2007-05-23       Impact factor: 3.616

Review 8.  Avian influenza virus (H5N1): a threat to human health.

Authors:  J S Malik Peiris; Menno D de Jong; Yi Guan
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

Review 9.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

10.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

View more
  19 in total

1.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

2.  Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.

Authors:  Sai V Vemula; Omar Amen; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Virus Res       Date:  2013-09-17       Impact factor: 3.303

3.  Cell culture-derived flu vaccine: Present and future.

Authors:  Alberto Pérez Rubio; Jose María Eiros
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

4.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

5.  Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.

Authors:  Anurag Sharma; Dinesh S Bangari; Manish Tandon; Harm Hogenesch; Suresh K Mittal
Journal:  Virus Res       Date:  2010-07-24       Impact factor: 3.303

6.  A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.

Authors:  Xiaofang Huang; Aykan Karabudak; Joseph D Comber; Mohan Philip; Tulin Morcol; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

7.  Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.

Authors:  Li Wang; Timothy Z Chang; Yuan He; Jong R Kim; Shelly Wang; Teena Mohan; Zachary Berman; S Mark Tompkins; Ralph A Tripp; Richard W Compans; Julie A Champion; Bao-Zhong Wang
Journal:  Nanomedicine       Date:  2016-09-10       Impact factor: 5.307

8.  Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Yu-Chih Yang; Ching Chou; Ming-Tsan Liu; Ho-Sheng Wu; Jia-Tsrong Chan; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

Review 10.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.